RECRUITING

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study's objective is to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC) of patients with Parkinson's Disease (PD) who experience impulse control disorders (ICDs) on impulse control symptoms and cognitive behaviors linked to ICDs: reinforcement learning and delay-discounting. This is a randomized sham-controlled cross-over trial. All patients will undergo a session of active rTMS and a session of sham rTMS, with the order of sessions randomized across participants. Following recruitment and eligibility screening, the eligible participants will undergo two sessions of rTMS (active and sham), immediately followed by neurocognitive tasks and questionnaires, no more than 1-2 weeks apart. Each session will have a duration of approximately 1-1.5 hours.

Official Title

The Effects of High-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Control Disorders in Parkinson's Disease Patients on Dopamine Replacement Therapy.

Quick Facts

Study Start:2024-05
Study Completion:2025-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06237868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Clinician-confirmed diagnosis of PD
  2. * Ability to provide informed consent, written and verbal
  3. * Clinician-diagnosed impulse control disorder or impulse control behaviors including punding/hobbyism and dopamine dysregulation syndrome
  4. * A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower
  5. * A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher
  6. * On dopamine-replacement therapy
  1. * History of seizures or epilepsy
  2. * History of brain lesions (such as multiple sclerosis, tumor) reported
  3. * History of vascular issues in the brain, such as stroke
  4. * History of a moderate to severe traumatic brain injury
  5. * Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher).
  6. * Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005)
  7. * Having had TMS done in the recent past (within a year)
  8. * Pregnancy assessed in female patients
  9. * Intracranial metallic objects (except for dental fillings)
  10. * Current use of substances or medications known to significantly reduce seizure threshold.

Contacts and Locations

Study Contact

Mariya V Cherkasova, PhD
CONTACT
2403673068
mariya.cherkasova@mail.wvu.edu

Principal Investigator

Mariya V Cherkasova, PhD
PRINCIPAL_INVESTIGATOR
West Virginia University

Study Locations (Sites)

West Virginia University Hospitals
Morgantown, West Virginia, 26505
United States

Collaborators and Investigators

Sponsor: West Virginia University

  • Mariya V Cherkasova, PhD, PRINCIPAL_INVESTIGATOR, West Virginia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05
Study Completion Date2025-02

Study Record Updates

Study Start Date2024-05
Study Completion Date2025-02

Terms related to this study

Additional Relevant MeSH Terms

  • Impulse Control Disorder
  • Parkinson Disease